Logo image of AFIB

ACUTUS MEDICAL INC (AFIB) Stock Fundamental Analysis

NASDAQ:AFIB - Nasdaq - US0051111096 - Common Stock - Currency: USD

0.09  -0.03 (-26.83%)

After market: 0.06 -0.03 (-33.33%)

Fundamental Rating

2

AFIB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. AFIB may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AFIB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AFIB has reported negative net income.
In the past year AFIB has reported a negative cash flow from operations.
AFIB had negative earnings in each of the past 5 years.
AFIB had a negative operating cash flow in each of the past 5 years.
AFIB Yearly Net Income VS EBIT VS OCF VS FCFAFIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

AFIB has a worse Return On Assets (-111.27%) than 83.94% of its industry peers.
Industry RankSector Rank
ROA -111.27%
ROE N/A
ROIC N/A
ROA(3y)-83.45%
ROA(5y)-79.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AFIB Yearly ROA, ROE, ROICAFIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 2K 4K 6K 8K

1.3 Margins

AFIB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AFIB Yearly Profit, Operating, Gross MarginsAFIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

AFIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AFIB remains at a similar level compared to 1 year ago.
The number of shares outstanding for AFIB has been increased compared to 5 years ago.
Compared to 1 year ago, AFIB has a worse debt to assets ratio.
AFIB Yearly Shares OutstandingAFIB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
AFIB Yearly Total Debt VS Total AssetsAFIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

AFIB has an Altman-Z score of -19.03. This is a bad value and indicates that AFIB is not financially healthy and even has some risk of bankruptcy.
AFIB's Altman-Z score of -19.03 is on the low side compared to the rest of the industry. AFIB is outperformed by 86.01% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.03
ROIC/WACCN/A
WACC11.53%
AFIB Yearly LT Debt VS Equity VS FCFAFIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

AFIB has a Current Ratio of 2.44. This indicates that AFIB is financially healthy and has no problem in meeting its short term obligations.
AFIB's Current ratio of 2.44 is on the low side compared to the rest of the industry. AFIB is outperformed by 64.25% of its industry peers.
A Quick Ratio of 2.22 indicates that AFIB has no problem at all paying its short term obligations.
With a Quick ratio value of 2.22, AFIB perfoms like the industry average, outperforming 46.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 2.22
AFIB Yearly Current Assets VS Current LiabilitesAFIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

AFIB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.71%, which is quite impressive.
The Revenue has decreased by -5.21% in the past year.
AFIB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.26% yearly.
EPS 1Y (TTM)34.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.72%
Revenue 1Y (TTM)-5.21%
Revenue growth 3Y79.26%
Revenue growth 5YN/A
Sales Q2Q%-12.95%

3.2 Future

AFIB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.68% yearly.
AFIB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 59.26% yearly.
EPS Next Y12.16%
EPS Next 2Y15.17%
EPS Next 3Y13.68%
EPS Next 5YN/A
Revenue Next Year31.1%
Revenue Next 2Y41.69%
Revenue Next 3Y46.08%
Revenue Next 5Y59.26%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AFIB Yearly Revenue VS EstimatesAFIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
AFIB Yearly EPS VS EstimatesAFIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AFIB. In the last year negative earnings were reported.
Also next year AFIB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFIB Price Earnings VS Forward Price EarningsAFIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFIB Per share dataAFIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

AFIB's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.17%
EPS Next 3Y13.68%

More info and screens

0

5. Dividend

5.1 Amount

AFIB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACUTUS MEDICAL INC

NASDAQ:AFIB (5/8/2024, 8:00:00 PM)

After market: 0.06 -0.03 (-33.33%)

0.09

-0.03 (-26.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-09 2024-05-09/amc
Earnings (Next)08-05 2024-08-05/amc
Inst Owners0.71%
Inst Owner Change-1.43%
Ins Owners3.41%
Ins Owner Change0%
Market Cap2.67M
Analysts43.33
Price Target1.53 (1600%)
Short Float %0.1%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.07%
Min Revenue beat(2)6.25%
Max Revenue beat(2)7.89%
Revenue beat(4)4
Avg Revenue beat(4)8.73%
Min Revenue beat(4)6.25%
Max Revenue beat(4)14.51%
Revenue beat(8)7
Avg Revenue beat(8)8.13%
Revenue beat(12)10
Avg Revenue beat(12)6.57%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-2.13
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS0.74
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -111.27%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.45%
ROA(5y)-79.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 114.66%
Cap/Sales 1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.44
Quick Ratio 2.22
Altman-Z -19.03
F-Score2
WACC11.53%
ROIC/WACCN/A
Cap/Depr(3y)110.7%
Cap/Depr(5y)163.05%
Cap/Sales(3y)28.38%
Cap/Sales(5y)67.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.72%
EPS Next Y12.16%
EPS Next 2Y15.17%
EPS Next 3Y13.68%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.21%
Revenue growth 3Y79.26%
Revenue growth 5YN/A
Sales Q2Q%-12.95%
Revenue Next Year31.1%
Revenue Next 2Y41.69%
Revenue Next 3Y46.08%
Revenue Next 5Y59.26%
EBIT growth 1Y20.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22%
EBIT Next 3Y18.78%
EBIT Next 5Y20.05%
FCF growth 1Y28.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.77%
OCF growth 3YN/A
OCF growth 5YN/A